Under the deal, Astellas will secure worldwide rights for commercializing CC8464 and back-up drug candidates to treat pain that were found via Chromocell’s Chromovert technology platform. Chromocell will
The tender offer, which is due to expire on 27 October, was made through Sun Pharma’s subsidiary Thea Acquisition for all of InSite Vision’s outstanding shares of common
The prosthesis features a small array of electrodes implanted into the brain. Scientists are evaluating it in human patients after its successful laboratory testing in animals. After receiving
Under the trial, Mesoblast carried out a post-hoc analysis in 30 patients who were randomized to receive either placebo or a single administration of 150 million MPCs (MPC-150-IM).
Novavax expects to start the trial during the first quarter of next year. The grant will also support the company’s regulatory licensing initiatives for WHO prequalification. After licensing,
Under the multinational, double-blind placebo-controlled Phase III HERCULES study, the company will enroll 92 patients at clinical sites across 17 countries. The primary endpoint of the study is
GvHD is a complication that can occur after a stem cell or bone marrow transplant. The newly transplanted donor cells attack the transplant recipient’s body. Under the new
About $29.5m will support studies on caring for people affected with hepatitis C virus (HCV). Awards totaling around $7.4m will fund research on rare conditions in response to
The deal will allow Lilly and its German partner, Boehringer Ingelheim, to launch the product in the US in late 2016. Basaglar secured approval from the US Food
The company worked with the US and European regulators to carry out its pivotal study under one global protocol for evaluating safety and efficacy of VTS-270. Vtesse will
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.